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Background: β-site APP cleaving enzyme 1 (BACE1) cleaves β-amyloid precursor protein (APP) to initiate the
production of β-amyloid (Aβ), the prime culprit in Alzheimer’s disease (AD). Dysregulation of the intracellular
trafficking of BACE1 may affect Aβ generation, contributing to AD pathology. In this study, we investigated whether
BACE1 trafficking and BACE1-mediated APP processing/Aβ generation are affected by sorting nexin 12 (SNX12), a
member of the sorting nexin (SNX) family that is involved in protein trafficking regulation.
Results: Herein, we find that SNX12 is widely expressed in brain tissues and is mainly localized in the early
endosomes. Overexpression of SNX12 does not affect the steady-state levels of APP, BACE1 or γ-secretase
components, but dramatically reduces the levels of Aβ, soluble APPβ and APP β-carboxyl terminal fragments.
Downregulation of SNX12 has the opposite effects. Modulation of SNX12 levels does not affect γ-secretase activity
or in vitro β-secretase activity. Further studies reveal that SNX12 interacts with BACE1 and downregulation of SNX12
accelerates BACE1 endocytosis and decreases steady-state level of cell surface BACE1. Finally, we find that the
SNX12 protein level is dramatically decreased in the brain of AD patients as compared to that of controls.
Conclusion: This study demonstrates that SNX12 can regulate the endocytosis of BACE1 through their interaction,
thereby affecting β-processing of APP for Aβ production. The reduced level of SNX12 in AD brains suggests that an
alteration of SNX12 may contribute to AD pathology. Therefore, inhibition of BACE1-mediated β-processing of APP
by regulating SNX12 might serve as an alternative strategy in developing an AD intervention.
Keywords: β-amyloid, β-amyloid precursor protein, β-site APP cleaving enzyme 1, Alzheimer’s disease, Intracellular
trafficking, Sorting nexin 12.Background
A major pathological hallmark of Alzheimer’s disease
(AD) is the formation of senile plaques in the brain. The
major components of senile plaques are heterogeneous
small peptides called β-amyloid (Aβ) [1]. Aβ peptides are
derived from the β-amyloid precursor protein (APP)
through sequential proteolytic cleavages; first by
β-secretase and then by γ-secretase. β-cleavage of APP
generates a soluble APPβ (sAPPβ) fragment and a
membrane-associated APP β-carboxyl terminal fragment
(βCTF). The latter can then be cleaved by γ-secretase to
release Aβ. γ-secretase is a high molecular weight* Correspondence: yunzhang@xmu.edu.cn.
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reproduction in any medium, provided the orcomplex that consists of presenilin 1 (PS1) or presenilin
2 (PS2), nicastrin, APH1 and PEN-2. Alternatively, APP
can be cleaved by α-secretase within the Aβ sequence to
release soluble APPα (sAPPα), which is neuroprotective,
precluding Aβ generation [1]. Accumulating evidence
has shown that overproduction/accumulation of Aβ pep-
tides in vulnerable brain regions is a primary cause in
the pathogenesis of AD [2-4]. Therefore, a dysregulation
of the proteins involved in Aβ generation, including the
altered intracellular trafficking/subcellular localization of
them, may increase Aβ generation and lead to disease
pathogenesis.
The type I transmembrane aspartyl protease, β-site APP
cleaving enzyme 1 (BACE1), is the putative β-secretase
[5-8]. Because its optimal activity requires an acidic envir-
onment, BACE1 is mainly localized in the early Golgi, late
Golgi/early endosomes, and endosomes. In addition,
BACE1 can be found at the cell surface [6,9-12]. Althoughtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and regulate its intracellular trafficking, such as reticulon/
Nogo [13-15], Golgi-localized γ-ear-containing ARF-
binding (GGA) [16-18] and sorting nexin 6 (SNX6) [19],
the detailed mechanism underlying BACE1 trafficking
regulation has yet to be fully elucidated.
Sorting nexins (SNXs) are a diverse group of cellular
trafficking proteins that are unified by the presence of a
phospholipid-binding (PX) motif. The ability of SNXs to
bind specific phospholipids, as well as their propensity
to form protein-protein complexes, suggests a role for
these proteins in membrane trafficking and protein sort-
ing [20-22]. Recently, some SNX members have been
found to mediate APP processing/Aβ generation
through regulating trafficking of AD associated proteins:
SNX17 can interact with APP in the early endosome and
downregulation of SNX17 leads to reduced steady-state
levels of APP with a concomitant increase in Aβ
production [23]. SNX33 can bind to the endocytic GTPase
dynamin and overexpression of SNX33 reduces the rate of
APP endocytosis in a dynamin-dependent manner, so that
APP is subjected to increased α-cleavage in cell surface
[24]. Moreover, SNX6 can associate with BACE1 and a re-
duction of SNX6 results in elevated steady-state levels of
BACE1 as well as increased retrograde transport of BACE1
in the endocytic pathway, increasing Aβ generation [19].
However, the functional roles of other SNX proteins, espe-
cially their involvement in AD, deserve further scrutiny.
In the present study, we demonstrate that another SNX
member, SNX12, can interact with BACE1 and affects its
intracellular trafficking, thus mediating β-processing of
APP in Aβ production.
Results
SNX12 affects the level of secreted Aβ
Several SNX family members have been found to modu-
late Aβ generation through different mechanisms.
Herein, we studied whether several other SNX proteins
can also affect Aβ generation. Our results showed that
in HEK293 cells stably expressing human APP Swedish
mutations (HEK-APPSwe), overexpression of one SNX
protein, SNX12, dramatically decreased the level of
secreted Aβ without affecting the level of full-length
APP (Figure 1A). When the level of SNX12 was downre-
gulated by RNAi, the level of full-length APP was not
altered but the level of secreted Aβ was significantly
increased (Figure 1B). To confirm the regulation of Aβ
by SNX12 in primary neurons, we downregulated
SNX12 using lentivirus infection in primary neurons
derived from APP/PS1/tau triple transgenic mice [25]
and found that the levels of Aβ40 and Aβ42 secreted by
primary neurons were indeed significantly increased
upon downregulation of SNX12 (Figure 1C).SNX12 is expressed in the brain and localized in early
endosomes
Information on the features and function of SNX12 is
very limited. Recently one study reported that SNX12 is
widely expressed in the adult mouse central nervous sys-
tem and thus suggested that SNX12 might regulate neur-
ite formation during cerebral cortical development [26].
Herein, we found that SNX12 is abundantly expressed
in mouse cerebrum and cerebellum in addition to
other tissues (Figure 2A). Further analysis showed that
the expression levels of SNX12 are similar in cortex,
hippocampus, cerebellum and midbrain (Figure 2B).
Since the major function of the SNX family proteins is
thought to be associated with endocytosis, endosomal
sorting, endosomal signaling, etc., we speculated that
SNX12 may be mainly localized in endosomal com-
partments. We transfected SNX12-EGFP into HeLa
cells and studied the localization of SNX12 in different
endosomal compartments by immunofluorescence. The
results showed that SNX12 co-localized well with an
early endosome marker, EEA1, but not with a late
endosome marker, cd63 (Figure 2C), indicating an
early endosome localization of SNX12.
SNX12 does not affect γ-secretase activity
To determine how SNX12 affects Aβ, we first investi-
gated whether SNX12 affects γ-secretase. The results
showed that neither overexpression (Figure 3A) nor
downregulation (Figure 3B) of SNX12 altered the pro-
tein levels of presenilin 1 amino-terminal fragment
(NTF) and nicastrin (NCT), two major components of
γ-secretase. Notch is another major substrate of
γ-secretase. When we overexpressed Notch NΔE, which
lacks the ectodomain of Notch1 and can be processed in
a ligand-independent manner by γ-secretase to produce
NICD [27], we found that overexpression of SNX12 did
not affect the γ-cleavage of Notch NΔE for NICD pro-
duction (Figure 3C). In addition, we overexpressed APP
βCTF (C99), the direct substrate of γ-secretase, in HEK
cells to avoid the interference of β-cleavage, and found
that overexpression of SNX12 did not affect the gener-
ation of Aβ40 or Aβ42 (Figure 3D). Together, these
results suggest that SNX12 does not affect the activity of
γ-secretase.
SNX12 affects the β-processing of APP but not in vitro
β-secretase activity
Next, we studied whether SNX12 affects the β-cleavage
of APP. Upon overexpression of SNX12, we found that
although the total level of BACE1 was not altered, the
levels of both APP βCTF and sAPPβ, the two direct pro-
ducts of the β-cleavage of APP, were markedly decreased
(Figure 4A). Downregulation of SNX12 increased the
levels of APP βCTF and sAPPβ without affecting the
Figure 1 SNX12 regulates Aβ generation. HEK-APPSwe cells were transfected with (A) SNX12 and control plasmids, or (B) two SNX12 siRNAs (1
and 2) and a control scrambled siRNA. Aβ in conditioned media and total APP and SNX12 in cell lysates were analyzed by Western blot. The
levels of Aβ were quantified by densitometry for comparison. N = 3, *: p< 0.05. (C) Primary neurons derived from APP/PS1/tau triple transgenic
mice at postnatal day 0 were infected with SNX12 shRNA or control lentiviral particles for 72 h. Neuron lysates were analyzed for APP, PS1-NTF,
BACE1, SNX12 and MAP2 by Western blot. Secreted Aβ40 and Aβ42 in conditioned media were quantified by ELISA. The levels of Aβ40 and Aβ42
were normalized to those of controls (set as one arbitrary units) for comparison. N = 3, *: p< 0.05.
Zhao et al. Molecular Neurodegeneration 2012, 7:30 Page 3 of 10
http://www.molecularneurodegeneration.com/content/7/1/30level of BACE1 (Figure 4B). APP ΔC57 lacks the last 57
carboxyl-terminal amino acids of APP and cleavage of
APP ΔC57 by β-secretase leads to direct production of
Aβ42. We found that in cells expressing human APP
ΔC57, overexpression of SNX12 significantly reduced
the level of secreted human Aβ42 (Figure 4C). Together,
these results suggest that SNX12 affects the β-processing of
APP. However, when SH-SY5Y cells transfected with
SNX12 and control plasmid were compared for
in vitro activity of BACE1 using a commercial kit,
we found no differences between them (Figure 4D), sug-
gesting that SNX12 does not affect the general enzymatic
activity of BACE1.SNX12 interacts with BACE1 but not APP
Since SNX12 does not affect the level/activity of BACE1,
SNX12 may modulate the β-cleavage of APP through
different mechanisms. Because we found that SNX12 is
localized in early endosomes and BACE1 has been
reported to also be localized in early endosomes, we co-
transfected SNX12-EGFP and BACE1-HA into HeLa
cells and carried out immunofluorescence studies. The
results showed that SNX12 co-localized with BACE1
(Figure 5A). In addition, in cells overexpressing SNX12-
Myc and BACE1-HA, an anti-HA antibody pulled down
SNX12, indicating an interaction between SNX12 and
BACE1 (Figure 5B). However, in cells overexpressing
Figure 2 SNX12 is abundantly expressed in mouse brain tissues and localized in the early endosomes. The expression of SNX12 in
various (A) tissues and (B) brain regions of two month old C57/Bl6 mice were analyzed by Western blot. (C) SNX12-EGFP was transfected into
HeLa cells. Cells were fixed, permeabilized, and incubated with antibodies against the early endosome marker EEA1 or the late endosome marker
cd63. After additional incubation with Alexa 594-conjugated secondary antibody, cells were examined with a fluorescence confocal microscope.
Green: SNX12; red: EEA1 or cd63.
Zhao et al. Molecular Neurodegeneration 2012, 7:30 Page 4 of 10
http://www.molecularneurodegeneration.com/content/7/1/30SNX12-Myc and APP, an anti-APP antibody (369) could
not pull down SNX12, indicating that SNX12 does not
interact with APP (Figure 5C). Moreover, we carried out
co-immunoprecipitation between endogenous SNX12
and endogenous BACE1 in SH-SY5Y cells and found
that an anti-SNX12 antibody pulled down BACE1 and
an anti-BACE1 antibody (689) pulled down SNX12, con-
firming the interaction between the two (Figure 5D).
SNX12 regulates the endocytosis of BACE1
Since the endosomal compartment is a major site for the
BACE1 cleavage of APP and Aβ generation, SNX12
might mediate the endocytosis of BACE1 through their
interaction and thus affect the β-processing of APP. To
address this, we carried out a cell surface protein bioti-
nylation assay and found that upon downregulation of
SNX12, the level of cell surface BACE1 was markedly
decreased, whereas the levels of cell surface APP, totalAPP and total BACE1 were not affected (Figure 6A).
Moreover, we studied endocytosis of cell surface BACE1.
Under same conditions, an observable endocytosis of
BACE1 in control cells occurred at about 15 min after
chasing, whereas in cells with SNX12 downregulation,
an observable endocytosis of BACE1 occurred early at
5 min after chasing (Figure 6B), suggesting that downre-
gulation of SNX12 can accelerate the endocytosis of
BACE1.
The level of SNX12 is decreased in the brain of AD
patients
Finally, we detected the level of SNX12 in the brain of
AD patients and age/sex matched controls. The results
showed that the level of SNX12 was dramatically
decreased in the brains of AD patients over that in con-
trols (Figure 7), suggesting a direct link between SNX12
changes and AD pathology.
Figure 3 SNX12 does not affect γ-secretase activity. HEK-APPSwe cells were transfected with (A) SNX12 and control plasmids, or (B) two
SNX12 siRNAs (1 and 2) and a control scrambled siRNA. Two γ-secretase components, PS1-NTF and nicastrin (NCT), were analyzed by Western
blot. (C) HEK 293 T cells were first transfected with Notch NΔE. After splitting equally, cells were transfected with SNX12 (+) or control (−)
plasmids. Notch NΔE and NICD in cell lysates were analyzed by Western blot. (D) HEK 293 T cells were first transfected with APP βCTF/C99. After
splitting equally, cells were transfected with SNX12 (+) or control (−) plasmids. Transfected C99 and SNX12 in cell lysates were analyzed by
Western blot. Aβ40 and Aβ42 in conditioned media were assayed by ELISA. N = 4.
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Aβ is generated from its precursor APP through sequen-
tial cleavages first by β-secretase/BACE1 and then by
γ-secretase, during their highly regulated trafficking
within the cell. Dysregulation in the intracellular traffick-
ing of these proteins may alter a proper interaction be-
tween APP and its two secretases, thereby affecting Aβ
production and contributing to disease pathogenesis.
The putative β-secretase, BACE1, cycles between the
secretory pathway compartments while BACE1 activity
resides in both the secretory pathway and the endo-
somes. The intracellular trafficking of BACE1 may be
affected by molecules that interact with it: some studies
found that BACE1 can interact with reticulon/Nogo pro-
teins, whose increased expression can block BACE1 in
the ER that has a neutral pH environment and thus in-
hibit BACE1 activity in Aβ generation [13-15]. In
addition, Golgi-localized γ-ear-containing ARF-binding
(GGA) proteins interact with BACE1 and regulate its
trafficking between the late Golgi and early endosomes;
depletion of GGA proteins increases the accumulation
of BACE1 in the acidic early endosome for enhanced
BACE1 stability and cleavage of APP [16-18]. More re-
cently, a SNX family member, SNX6, has also been found
to be associated with BACE1 and a reduction of SNX6
results in elevated steady-state levels of BACE1 as well as
increased retrograde transport of BACE1 in the endocytic
pathway, causing increased Aβ generation [19].In this study, we demonstrate that SNX12, another
SNX family member, also interacts with BACE1 and
affects the β-cleavage of APP. Although the steady-state
level of BACE1 was not affected upon modulation of
SNX12, downregulation of SNX12 resulted in increased
BACE1 endocytosis and Aβ generation, similar to that
of SNX6; and overexpression of SNX12 reduced the
production of Aβ. Importantly, we found that SNX12
was abundantly expressed in brain tissues and the level
of SNX12 was dramatically decreased in the brain of
AD patients when compared to that of controls, sug-
gesting a direct link between SNX12 alteration and AD
pathology.
SNX family members share a conserved PX motif
that acts as a phosphoinositide-binding site for target-
ing the SNX protein to phosphoinositide-enriched
membranes [28]. These proteins have been proposed
to play a role in membrane trafficking and protein
sorting [20-22]. In addition to SNX12 and SNX6
which interact with BACE1 and affect APP processing/
Aβ generation, several other SNX members such as
SNX17 [23] and SNX33 [24] have also been found to
mediate APP processing/Aβ generation through regu-
lating the intracellular trafficking of APP. Together,
these results suggest that SNX members may partici-
pate in AD pathology through modulating the traffick-
ing of various AD-associated proteins, which deserves
further investigation.
Figure 4 SNX12 affects β-processing of APP but not BACE1 level or activity. SH-SY5Y cells were transfected with (A) SNX12 and control
plasmids, or (B) two SNX12 siRNAs (1 and 2) and a control scrambled siRNA. sAPPβ in conditioned media and total APP, APP βCTF and BACE1 in
cell lysates were analyzed by Western blot. (C) HEK 293 T cells were first transfected with APP ΔC57. After splitting equally, cells were transfected
with SNX12 (+) or control (−) plasmids. Transfected APP ΔC57 and SNX12 in cell lysates were analyzed by Western blot. Aβ42 in conditioned
media were assayed by ELISA. N = 4, *: p< 0.05. (D) SH-SY5Y cells were transfected with SNX12 and control plasmids. Cell lysates were assayed for
BACE1 activity using a commercial kit. N = 3.
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Our studies have demonstrated that SNX12 may partici-
pate in AD pathology by interacting with BACE1,
thereby regulating BACE1 intracellular trafficking and
BACE1-mediated β-processing of APP in Aβ production.
The reduction of SNX12 in the brain of AD patients
may accelerate the endocytosis of BACE1 and lead to
increased Aβ generation. As BACE1 represents a favored
target for AD intervention, inhibition of BACE1-
mediated β-processing of APP by regulating SNX12
might provide an alternative strategy for developing AD
therapeutics.
Methods
Cell culture, plasmids and transfection
HEK293T and SH-SY5Y cells were maintained in DMEM
(Hyclone) supplemented with 10% FBS (Hyclone) and 1%
penicillin/streptomycin. HEK cells stably expressing
human APP Swedish mutations (HEK-APPSwe) were
maintained in the same media with the addition of
400 μg/mL G418 (Invitrogen). Hela cells were maintainedin RPMI-1640 (Hyclone) supplemented with 10% FBS and
1% penicillin/streptomycin. Maintenance of N2a cells sta-
bly expressing human APP695 (N2a-APP) was as previ-
ously reported [29]. Primary neurons derived from APP/
PS1/tau triple transgenic mice collected at postnatal day 0
were cultured in Neurobasal medium supplemented with
B-27 (Invitrogen).
The pCI-neo-SNX12/myc plasmid and the pCI-neo
control plasmid were kindly provided by Dr. Wanjin
Hong. The BACE1-HA plasmid was kindly provided by
Dr. Riqiang Yan. The APP βCTF (containing the last 99
carboxyl-amino acids, C99) and ΔC57 (lacking the last
57 carboxyl-terminal amino acids) fragments were
inserted into the pcDNA3.1-Myc/His plasmid (Invitro-
gen) to generate plasmids. The SNX12-EGFP plasmid
was constructed by subcloning SNX12 into the pEGFP-
N1 plasmid (Clontech). Notch NΔE plasmid was as pre-
viously reported [27,30].
Transient transfection was performed by using Turbo-
Fect reagent (Fermentas), following the manufacturer’s
protocol.
Figure 5 SNX12 interacts with BACE1. (A) HeLa cells were co-transfected with SNX12-EGFP (in green) and BACE1-HA. Cells were then fixed,
permeabilized and immunostained sequentially with primary antibodies against HA and secondary antibodies conjugated with Alexa Fluor 594
(to indicate BACE1, in red). Samples were examined by a fluorescence confocal microscope. (B) BACE1-HA was co-transfected with control (−) or
SNX12-Myc (+) into HEK 293T cells. Equal protein amounts of cell lysates were used for immunoprecipitation (IP) with an anti-HA antibody or
control IgG. Immunoprecipitated proteins were subjected to Western blot with anti-HA or anti-Myc antibodies to detect BACE1 or SNX12,
respectively. Ten percent of cell lysates were used as input. (C) HEK-APPSwe cells were transfected with control (−) or SNX12-Myc (+). Equal
protein amounts of cell lysates were subjected to IP with control IgG or the anti-APP antibody 369. Immunoprecipitated proteins and input were
subjected to Western blot. (D) Equal protein amounts of SH-SY5Y cell lysates were subjected to IP with control IgG, anti-SNX12 antibody, or the
anti-BACE1 antibody 689. Immunoprecipitated proteins and input were subjected to Western blot analysis.
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Antibodies used in this study include: anti-Myc antibody
(9E10) from Santa Cruz Biotechnology; anti-HA and
anti-SNX12 antibodies from Gene Tex; anti-α-tubulin
and anti-β-actin antibodies and control IgG from Sigma;
anti-Aβ antibody (6E10) from Covance; and anti-EEA1
and anti-cd63 antibodies from Abcam. Anti-BACE1antibody 689 and anti-APP antibody 369 were kindly
provided by Dr. Huaxi Xu. Anti-BACE1 antibody 3D5
was kindly provided by Dr. Robert Vassar.
Cells were lysed in a lysis buffer containing 10 mM
Tris–HCl (pH 7.8), 1 mM EDTA, 150 mM NaCl, 1%
Nonidet P-40 and supplemented with a protease inhibi-
tor mixture. Equal protein amounts of cell lysates were
Figure 6 Downregulation of SNX12 accelerates the endocytosis of BACE1 and decreases the cell surface level of BACE1. (A) After RNAi
downregulation of SNX12, SH-SY5Y cells were subjected to biotinylation. Cell lysates were affinity-precipitated with streptavidin-agarose beads to
pull down biotinylated proteins that were at the cell surface. The levels of biotinylated BACE1 and APP, as well as their total protein levels, were
analyzed by Western blot. Cell surface levels of BACE1 were quantified by densitometry and normalized to that of control (set as one arbitrary
unit) for comparison. N = 3, *: p< 0.05. (B) Upon downregulation of SNX12 by RNAi, protein at the cell surface of SH-SY5Y cells was labeled with
EZ-Link Sulfo-SS-Biotin. After chasing at 37 °C for the indicated times, cells were treated with glutathione at 4 °C to cleave biotin from remaining
cell surface proteins. Cell lysates were affinity-precipitated with streptavidin-agarose beads. The levels of biotinylated (i.e. endocytosed) BACE1
were analyzed by Western blot. The levels of endocytotic BACE1 were quantified by densitometry and normalized to those of five percent of
total (T) BACE1 (before chasing) for comparison. N = 3, *: p< 0.05.
Zhao et al. Molecular Neurodegeneration 2012, 7:30 Page 8 of 10
http://www.molecularneurodegeneration.com/content/7/1/30subjected to SDS-PAGE and Western blot with indicated
antibodies.
SNX12 RNA interference
For RNA interference (RNAi) to downregulate
human SNX12 expression, two SNX12 targeting siR-
NAs (1: 5’- ATGAGCTGGAGAGAGATAG-3’; and 2: 5’-
TGAACGCTGCCTACACATG-3’) and a scrambled control
siRNA (Invitrogen) were transfected into cells using Lipo-
fectamine RNAiMAX reagent (Invitrogen), following the
manufacturer’s protocol.
Lentivirus infection
SNX12 shRNA and control lentiviral particles were pur-
chased from Santa Cruz Biotechnology. These viruses
were used to infect APP/PS1/tau primary neurons for
72 h before experiments.Immunoprecipitation
Cells were lysed in a lysis buffer. Cell lysates were pre-
cleared with rProtein A sepharose (GE) at 4 °C for 1 h
and then incubated with rProtein A sepharose and the
indicated antibodies or IgG at 4 °C overnight. Immuno-
precipitated proteins were analyzed by Western blot.
Aβ assay
To detect the total level of secreted Aβ, cells were trans-
fected for 24-48 h and then incubated with DMEM for
4-6 h. Conditioned media was then collected and incu-
bated with trichloroacetic acid (1:9 v/v) overnight at 4 °C
for protein precipitation. Precipitated proteins were sub-
jected to Western blot with the anti-Aβ antibody 6E10.
Alternatively, Conditioned media were assayed by ELISA
to detect Aβ40 and Aβ42, using commercial ELISA kits
(Invitrogen).
Figure 7 The level of SNX12 is decreased in AD brains. Equal
amounts of protein lysates from the brains of AD patients and age/
sex matched controls (C) were analyzed for SNX12 by Western blot.
Protein levels were quantitated by densitometry and normalized to
those of GAPDH for statistical comparison to those of controls. Lane
numbers are the same as numbers in Table 1. N = 5, *: p< 0.05.
Table 1 Human brain samples used in this study
Number* Case Sex Age
1 Non-AD Female 82
2 AD Female 83
3 Non-AD Female 76
4 AD Female 78
5 Non-AD Male 83
6 AD Male 83
7 Non-AD Male 68
8 AD Male 67
9 Non-AD Male 78
10 AD Male 76
*: Numbers are the same as lane numbers in Figure 7.
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The in vitro BACE1 activity was assayed by using the
β-Secretase Activity Assay Kit, Fluorogenic (Calbiochem),
following the manufacturer’s protocol.
Immunofluorescence
Treated cells were fixed in 4% paraformaldehyde and
permeabilized with 0.2% Triton-X100. Cells were then
incubated with the indicated primary antibodies, fol-
lowed by incubation with Alexa 594-conjugated second-
ary antibody (Invitrogen). Specimens were examined
with a ZEISS LSM 5 Exciter confocal microscope and
images were captured using the ZEN software.
Cell surface biotinylation
Treated cells were washed with ice-cold phosphate-
buffered saline containing 1 mM each of CaCl2 and
MgCl2, and incubated at 4 °C with 0.5 mg/mL Sulfo-
NHS-LC-biotin (Thermo Scientific, Rockford, IL). Cells
were then lysed and lysates were affinity-precipitated
with streptavidin-agarose beads (Thermo Scientific). Bio-
tinylated proteins were subjected to Western blot
analysis.
Cell surface protein endocytosis assay
Cells were first biotinylated with cleavable EZ-Link
Sulfo-SS-Biotin (Thermo Scientific). After chasing at
37 °C for the indicated times, cells were treated with
cold glutathione buffer at 4 °C to cleave biotin from cell
surface proteins. The remaining biotinylated proteins
represent the endocytosed proteins and were affinity-precipitated with streptavidin-agarose beads for further
Western blot analysis.
SNX12 level in human brains
Brain cortical region samples of AD patients and age-
and sex-matched controls were kindly provided by Dr.
Yong Shen. More detailed information of these samples
was listed in Table 1. Samples were lysed in RIPA buffer
and equal protein amounts of samples were subjected to
Western blot to detect the level of SNX12.
Statistical analysis
Two-tailed paired t-test was carried out for statistical
analysis.
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